KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Cardlytics (CDLX) EBIAT (2017 - 2025)

Cardlytics (CDLX) has disclosed EBIAT for 9 consecutive years, with -$8.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT rose 47.08% year-over-year to -$8.2 million, compared with a TTM value of -$103.5 million through Dec 2025, up 45.33%, and an annual FY2025 reading of -$103.5 million, up 45.33% over the prior year.
  • EBIAT was -$8.2 million for Q4 2025 at Cardlytics, up from -$72.7 million in the prior quarter.
  • Across five years, EBIAT topped out at $33.0 million in Q1 2022 and bottomed at -$378.3 million in Q4 2022.
  • Average EBIAT over 5 years is -$51.1 million, with a median of -$23.7 million recorded in 2023.
  • Peak annual rise in EBIAT hit 232.71% in 2022, while the deepest fall reached 3096.27% in 2022.
  • Year by year, EBIAT stood at -$11.8 million in 2021, then crashed by 3096.27% to -$378.3 million in 2022, then soared by 73.34% to -$100.8 million in 2023, then soared by 84.54% to -$15.6 million in 2024, then skyrocketed by 47.08% to -$8.2 million in 2025.
  • Business Quant data shows EBIAT for CDLX at -$8.2 million in Q4 2025, -$72.7 million in Q3 2025, and -$9.3 million in Q2 2025.